786
Abstract Views
174
PDF Download
Case-Study

Safety of metamizole analgesic therapy in patients with dyspepsia syndrome: a case report

Khoirul Anam University of Surabaya, Indonesia Correspondence a6.apt1@gmail.com
,
Rina Widiyawat University of Surabaya, Indonesia Correspondence rhienawidi@gmail.com
,
Tita Sugesti Mardi Waluyo Regional Public Hospital, Indonesia Correspondence tita.sugesti81@gmail.com
,
M. Hari Pristantiningtyas Mardi Waluyo Regional Public Hospital, Indonesia Correspondence maditoo@gmail.com
,
Herya Putra Dharma Mardi Waluyo Regional Public Hospital, Indonesia Correspondence heryaputra@gmail.com
,
Muhammad Muchlis Mardi Waluyo Regional Public Hospital, Indonesia Correspondence paklurah010670@gmail.com
,
Jainuri Erik Pratama Dr. Kariadi Central General Hospital, Indonesia Correspondence erik.rssa@gmail.com
,
Adji Prayitno Setiadi University of Surabaya, Indonesia Correspondence adji_ps@staff.ubaya.ac.id
,
Marisca Evalina Gondokesumo Universitas Surabaya, Indonesia Correspondence marisca@staff.ubaya.ac.id
Pages 66-70
Browse this journal

Abstract

The selection of drugs in patients who have experienced dyspepsia syndrome needs to be studied for its use. Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that are effective in controlling various inflammatory conditions and treating inflammatory symptoms such as pain but are limited in their use in patients with dyspepsia. We report case of patients with metamizole NSAIDs during three days of hospitalization with a diagnosis of dyspepsia. Other side effects such as cardiovascular, neurological disorders and agranulocytosis can also occur with the use of metamizole. There were no side effects that exacerbated dyspepsia symptoms in patients or other side effects during the three days of using metamizol. It can be concluded that short-term metamizole therapy is safe for use in patients with dyspeptic syndrome. Concomitant use with gastric acid blocking agents such as H2 receptor antagonists may also reduce the effects of gastrointestinal disturbances.

There is no Figure or data content available for this article

References

  • REFERENCE
  • Baigent, C., Bhala, N., Emberson, J., Merhi, A., Abramson, S., Arber, N., Baron, J. A., Bombardier, C., Cannon, C., Farkouh, M. E., FitzGerald, G. A., Goss, P., Halls, H., Hawk, E., Hawkey, C., Hennekens, C., Hochberg, M., Holland, L. E., Kearney, P. M., Yau, F. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet, 382(9894), 769. https://doi.org/10.1016/S0140-6736(13)60900-9
  • Black, C. J., Houghton, L. A., & Ford, A. C. (2018). Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. Therapeutic Advances in Gastroenterology, 11, 175628481880559. https://doi.org/10.1177/1756284818805597
  • Black, C. J., Paine, P. A., Agrawal, A., Aziz, I., Eugenicos, M. P., Houghton, L. A., Hungin, P., Overshott, R., Vasant, D. H., Rudd, S., Winning, R. C., Corsetti, M., & Ford, A. C. (2022). British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut, 71(9), 1697. https://doi.org/10.1136/GUTJNL-2022-327737
  • Chaves, J., Pita, I., Libânio, D., & Pimentel-Nunes, P. (2022). Pharmacological Treatment of Functional Dyspepsia: An Old Story Revisited or a New Story to Be Told? A Clinical Review. GE Portuguese journal of gastroenterology, 30(2), 86–97. https://doi.org/10.1159/000526674
  • de Leeuw, T. G., Dirckx, M., Gonzalez Candel, A., Scoones, G. P., Huygen, F. J. P. M., & de Wildt, S. N. (2017). The use of dipyrone (metamizol) as an analgesic in children: What is the evidence? A review. Pediatric Anesthesia, 27(12), 1193–1201. https://doi.org/10.1111/pan.13257
  • Drossman, D. A. (2016). Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV. Gastroenterology, 150(6), 1262-1279.e2. https://doi.org/10.1053/j.gastro.2016.02.032
  • Ford, A. C., & Moayyedi, P. (2013). Dyspepsia. BMJ, 347(aug29 1), f5059–f5059. https://doi.org/10.1136/bmj.f5059
  • Ford, A. C., Marwaha, A., Sood, R., & Moayyedi, P. (2015). Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut, 64(7), 1049–1057. https://doi.org/10.1136/gutjnl-2014-307843
  • Ghlichloo I, Gerriets V. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547742/
  • Harahap, M. W., & Ahmad, M. R. (2022). Perbandingan antara Dexametason dan Metamizol Intravena terhadap Kadar Neutrofil Pasca Seksio Sesarea. Jurnal Anestesi Obstetri Indonesia, 5(3).
  • Harmon, R. C., & Peura, D. A. (2010). Evaluation and management of dyspepsia. Therapeutic advances in gastroenterology, 3(2), 87–98. https://doi.org/10.1177/1756283X09356590
  • Jasiecka, A., Ma?lanka, T., & Jaroszewski, J. J. (2014). Pharmacological characteristics of metamizole. Polish journal of veterinary sciences, 17(1), 207–214. https://doi.org/10.2478/pjvs-2014-0030
  • Konijnenbelt-Peters J, Van der Heijden Ch, Ekhart C, Bos J, Bruhn J, Kramers C. (2017). Metamizole (Dipyrone) as an Alternative Agent in Postoperative Analgesia in Patients with Contraindications for Nonsteroidal Anti-In?ammatory Drugs. Pain Practice; 17 (3): 402–408
  • Kötter, T., da Costa, B. R., Fässler, M., Blozik, E., Linde, K., Jüni, P., Reichenbach, S., & Scherer, M. (2015). Metamizole-Associated Adverse Events: A Systematic Review and Meta-Analysis. PLOS ONE, 10(4), e0122918. https://doi.org/10.1371/JOURNAL.PONE.0122918
  • Kotter, T., et al. (2015). Metamizole - Associated Adverse Events : A Systematic Review and Meta - Analysis, PLOS ONE, DOI : 10.1371
  • Kumar, S., Thakur, P. K., Sowmya, K., Priyanka, S., & Kumar, S. (2016). EVALUATION OF PRESCRIBING PATTERN OF NSAIDS IN SOUTH INDIAN TEACHING HOSPITAL. Journal of Chitwan Medical College, 6(18), 54–58. www.jcmc.cmc.edu.np
  • Kurniawati, M., Ikawati, Z., & Raharjo, B. (2012). THE EVALUATION OF METAMIZOLE USE IN SOME PLACES OF PHARMACY SERVICE IN CILACAP COUNTY. Jurnal Manajemen Dan Pelayanan Farmasi, 2(1).
  • Madisch, A., Andresen, V., Enck, P., Labenz, J., Frieling, T., & Schemann, M. (2018). The Diagnosis and Treatment of Functional Dyspepsia. Deutsches Arzteblatt international, 115(13), 222–232. https://doi.org/10.3238/arztebl.2018.0222
  • Miljkovic, M., Dragojevic-Simic, V., Rancic, N., Simic, R., Pekez-Pavlisko, T., Kovacevic, A., & Stamenkovic, D. (2018). Metamizole Utilization and Expenditure During 6-Year Period: Serbia vs. Croatia. Frontiers in public health, 6, 213. https://doi.org/10.3389/fpubh.2018.00213
  • Nabila, H., Dewi, N. M. A. R., & Lestarini, I. A. (2022). Evaluasi pola penggunaan obat dispepsia berdasarkan indikator WHO (World Health Organization) pada pasien rawat jalan Puskesmas Karang Taliwang tahun 2019. Sasambo Journal of Pharmacy, 3(1), 11–17. https://doi.org/10.29303/sjp.v3i1.139
  • Nikolova, I., Petkova, V., Tencheva, J., Benbasat, N., Voinikov, J., & Danchev, N. (2013). Metamizole: A Review Profile of a Well-Known “Forgotten” Drug. Part II: Clinical Profile. Biotechnology & Biotechnological Equipment, 27(2), 3605–3619. https://doi.org/10.5504/BBEQ.2012.0135
  • Nikolova, I., Tencheva, J., Voinikov, J., Petkova, V., Benbasat, N., & Danchev, N. (2014). Biotechnology & Biotechnological Equipment Metamizole: A Review Profile of a Well-Known “Forgotten” Drug. Part I: Pharmaceutical and Nonclinical Profile. https://doi.org/10.5504/BBEQ.2012.0089
  • Oustamanolakis, P., & Tack, J. (2012). Dyspepsia: organic versus functional. Journal of clinical gastroenterology, 46(3), 175–190. https://doi.org/10.1097/MCG.0b013e318241b335
  • Pinto-Sanchez, M. I., Yuan, Y., Bercik, P., & Moayyedi, P. (2017). Proton pump inhibitors for functional dyspepsia. The Cochrane database of systematic reviews, 3(3), CD011194. https://doi.org/10.1002/14651858.CD011194.pub2
  • Quigley E. M. (2015). Prokinetics in the Management of Functional Gastrointestinal Disorders. Journal of neurogastroenterology and motility, 21(3), 330–336. https://doi.org/10.5056/jnm15094
  • Sakaguchi, M., Takao, M., Ohyama, Y., Oka, H., Yamashita, H., Fukuchi, T., Ashida, K., Murotani, M., Murotani, M., Majima, K., Morikawa, H., Hashimoto, T., Kiyota, K., Esaki, H., Amemoto, K., Isowa, G., & Takao, F. (2012). Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia. World journal of gastroenterology, 18(13), 1517–1524. https://doi.org/10.3748/wjg.v18.i13.1517
  • Savarino, V., Marabotto, E., Zentilin, P., Furnari, M., Bodini, G., de Maria, C., Pellegatta, G., Coppo, C., & Savarino, E. (2018). Proton pump inhibitors: use and misuse in the clinical setting. Expert Review of Clinical Pharmacology, 11(11), 1123–1134. https://doi.org/10.1080/17512433.2018.1531703
  • Tai, F. W. D., & McAlindon, M. E. (2021). Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clinical Medicine, 21(2), 131. https://doi.org/10.7861/CLINMED.2021-0039
  • Voiosu, T. A., Giurcan, R., Voiosu, A. M., Mihail, & Voiosu, R. (2013). Functional Dyspepsia Today. Mædica, 8(1), 68. /pmc/articles/PMC3749766/
  • Yarandi, S. S., & Christie, J. (2013). Functional Dyspepsia in Review: Pathophysiology and Challenges in the Diagnosis and Management due to Coexisting Gastroesophageal Reflux Disease and Irritable Bowel Syndrome. Gastroenterology Research and Practice, 2013, 1–8. https://doi.org/10.1155/2013/351086
There is no Supplemental content for this article.

How to Cite This

Anam, K., Widiyawat, R., Sugesti, T., Pristantiningtyas, M. H., Dharma, H. P., Muchlis, M., … Gondokesumo, M. E. (2023). Safety of metamizole analgesic therapy in patients with dyspepsia syndrome: a case report. Jurnal Teknologi Laboratorium, 12(2), 66–70. https://doi.org/10.29238/teknolabjournal.v12i2.443

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Verify authenticity via CrossMark

Copyright and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

  • BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability

All data generated during this study are included in this published article [and its supplementary information files].